Bristol-Myers Squibb (NYSE:BMY) and Evotec have advanced molecular glue candidate BMS-986506 into Phase 1 trials for clear cell renal cell carcinoma. The program marks the first clinical-stage asset ...
Scientists develop a blood test that detects Alzheimer’s by measuring protein structural changes rather than protein quantity.